MedicalMinute: Next Steps Following TNF Inhibitor Failure in IBD

Learn about current guideline recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and review key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 337 KB
Released: May 24, 2021


Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb

Related Content

Drs. Anita Afzali, Millie Long, David Hudesman on latest IBD treatments, therapeutic challenges, individualized care, health inequity from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Released: May 20, 2022

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Expert slides from Clinical Care Options (CCO) on new data from ECCO 2022 17th Congress Meeting in patients with Crohn disease and ulcerative colitis

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings